Demirci Büşra, Özkaya-Parlakay Aslınur, Yılmaz Mehmet, Ekici Hasan, Erçel Mahmut Mert, Türker Ergün Gonca, Yücel Sevinç Püren
Department of Pediatrics, Ankara Bilkent City Hospital, 06800 Ankara, Turkey.
Pediatric Infectious Diseases Unit, Ankara Bilkent City Hospital, Yıldırım Beyazıt University, 06800 Ankara, Turkey.
J Trop Pediatr. 2025 Jun 7;71(4). doi: 10.1093/tropej/fmaf024.
RSV is a major health concern for infants. A new long-acting anti-RSV monoclonal antibody has been introduced in some countries. This study aims to assess pregnant women's awareness of RSV and their attitudes toward infant immunization with the anti-RSV monoclonal antibody. A survey on the RSV mAb was conducted with 217 pregnant women, consisting of 28 questions on sociodemographic characteristics, knowledge of RSV infection and the RSV mAb, and attitudes toward giving the mAb to their infant. Pregnant women were specifically surveyed about the use of nirsevimab. Among the participants, 18.5% reported that their child had previously experienced an RSV infection, with 47.6% requiring hospitalization. Willingness expressed by 50.7% to get the RSV mAb, 27.8% were undecided, and 21.6% would not get immunized. The main reason for refusal was lack of information (67.3%). Notably, 58.4% of undecided mothers would consider the RSV mAb if included in the routine immunization schedule. Multiple logistic regression analysis revealed that "having previously heard of the RSV mAb" and "receipt of other nonroutine vaccines" were independent factors influencing the consideration of the RSV mAb. A thorough literature review revealed no other studies assessing pregnant women's attitudes toward RSV mAb; it showed they would be more willing to accept it if included in Turkey's national vaccine programs. Further studies are needed globally to find if RSV vaccination rates increase if the benefits of infection protection and detailed information about the RSV vaccine are provided to mothers or families.
呼吸道合胞病毒（RSV）是婴幼儿健康的主要关注点。一种新型长效抗RSV单克隆抗体已在一些国家推出。本研究旨在评估孕妇对RSV的认知以及她们对婴儿接种抗RSV单克隆抗体的态度。对217名孕妇进行了关于RSV单克隆抗体的调查，包括28个关于社会人口学特征、RSV感染及RSV单克隆抗体知识，以及对给婴儿接种该单克隆抗体的态度的问题。特别对孕妇进行了关于使用nirsevimab的调查。在参与者中，18.5%报告其孩子曾感染过RSV，其中47.6%需要住院治疗。50.7%的人表示愿意接种RSV单克隆抗体，27.8%的人未决定，21.6%的人不愿接种。拒绝的主要原因是缺乏信息（67.3%）。值得注意的是，如果将RSV单克隆抗体纳入常规免疫计划，58.4%未决定的母亲会考虑接种。多因素logistic回归分析显示，“之前听说过RSV单克隆抗体”和“接种过其他非常规疫苗”是影响考虑接种RSV单克隆抗体的独立因素。全面的文献综述显示，没有其他研究评估孕妇对RSV单克隆抗体的态度；结果表明，如果将其纳入土耳其国家疫苗计划，她们会更愿意接受。全球还需要进一步研究，以确定如果向母亲或家庭提供感染防护益处及RSV疫苗的详细信息，RSV疫苗接种率是否会提高。
